<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01838070</url>
  </required_header>
  <id_info>
    <org_study_id>HAF85</org_study_id>
    <secondary_id>U1111-1127-7211</secondary_id>
    <nct_id>NCT01838070</nct_id>
  </id_info>
  <brief_title>Regulatory Post-Marketing Surveillance Study for Hepatitis A Vaccine (AVAXIM 160U)</brief_title>
  <official_title>Regulatory Post-Marketing Surveillance (PMS) Study for AVAXIM 160U (Hepatitis A Vaccine)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This safety surveillance study is being conducted in accordance with Korea Food and Drug
      Administration (KFDA) &quot;Basic standard for reexamination of new drug&quot;.

      Primary objective:

        -  To assess the safety of AVAXIM 160U (Hepatitis A vaccine) administered under the routine
           practice, according to Korea Food and Drug Administration &quot;Basic standard for
           reexamination of new drug&quot; based on the pharmaceutical law in Korea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted under the real clinical practices in accordance with Korea Food
      and Drug Administration &quot;Basic standard for reexamination of new drug&quot;.

      No vaccine will be provided and/or administered as part of this protocol, however only
      participants that has received AVAXIM 160U vaccine administered under the routine practice
      according to Summary of Product Characteristics will be part of the surveillance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety profile in terms of solicited and unsolicited adverse events following the administration of AVAXIM 160U vaccine</measure>
    <time_frame>Day 0 up to 30 Days post-vaccination</time_frame>
    <description>Solicited injection site: Pain, Erythema, and Swelling: Solicited Systemic Reactions: Fever (temperature), headache, and myalgia. Unsolicited averse events including non serious and serious adverse events.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">614</enrollment>
  <condition>Hepatitis A</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <description>Participants that has received AVAXIM 160U vaccine administered under the routine practice according to Summary of Product Characteristics</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who have received AVAXIM 160U (Hepatitis A Vaccine) according to Summary of
        Product Characteristics (SmPC)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects aged 16 years and older

          -  Informed consent signed by the subject and by parent or legal representative for
             subject aged 16 to 19 years

          -  Informed consent sign by subject for subject aged of 20 year of age and older

          -  Receipt of AVAXIM 160U according to Summary of Product Characteristics (SmPC).

        Exclusion Criteria:

          -  Contraindications to vaccination according to AVAXIM 160U Summary of Product
             Characteristics (SmPC)

          -  Subject is known to be pregnant, or lactating, or of childbearing potential (to be
             considered of non-childbearing potential, a female must be pre-menarche or
             post-menopausal for at least 1 year, surgically sterile, or using an effective method
             of contraception or abstinence for at least 4 weeks prior to the vaccination until at
             least 4 weeks after)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>120 752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2013</study_first_submitted>
  <study_first_submitted_qc>April 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2013</study_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis A</keyword>
  <keyword>Hepatitis A vaccine</keyword>
  <keyword>AVAXIM 160U</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

